2. Signaling Pathways
  3. Immunology/Inflammation
  4. MHC
  5. MHC II Isoform

MHC II

MHC class II (MHC II) molecules are central regulators of adaptive immunity because they present processed extracellular peptide antigens to CD4+ T cells, thereby initiating helper T-cell responses and coordinating downstream humoral and cellular immunity[1][2]. During antigen processing, newly synthesized MHC II α- and β-chains assemble with the invariant chain, traffic through the endosomal pathway, and acquire antigenic peptides after proteolytic processing and peptide editing mediated by HLA-DM and related accessory molecules[1][3][4]. This antigen-presentation pathway shapes the peptide repertoire displayed by antigen-presenting cells and directly influences T-cell activation, tolerance, and immune surveillance[1][4][5]. In disease settings, MHC II polymorphisms are strongly associated with susceptibility to autoimmune disorders because allele-dependent peptide presentation can alter the selection and activation of autoreactive CD4+ T cells[5][6]. Human MHC II consists primarily of the classical HLA-DR, HLA-DQ, and HLA-DP isotypes, which share the common function of peptide presentation but differ in genetic organization, peptide-binding characteristics, and requirements for intracellular assembly and peptide loading[2][7]. Compared with related isotypes, HLA-DR, HLA-DQ, and HLA-DP exhibit distinct interactions with antigen-processing machinery, resulting in differences in peptide repertoire generation and immune recognition[7]. For experimental applications, modulation of MHC II antigen presentation commonly focuses on accessory regulators such as HLA-DM and HLA-DO, which influence peptide exchange and repertoire selection rather than acting as direct receptor agonists or inhibitors[3][4].

MHC II Related Products (8):

Cat. No. Product Name Effect Purity
  • HY-P1745
    InsB (9-23)
    		98.98%
    InsB (9-23) (Insulin B chain (9-23)) is an HLA-DQ8-restricted insulin B-chain peptide composed of amino acid residues 9-23. InsB (9-23) serves as a major MHC II class-restricted antigen. InsB (9-23) supports the recognition and activation of T cells, stimulates the secretion of IFN-γ and cytokines, and induces cross-reactive immune responses. InsB (9-23)-specific CD4 T cells can initiate diabetes. InsB (9-23) can be used in research related to type 1 diabetes and autoimmune diabetes.
  • HY-P5502A
    Influenza NP (311-325) TFA
    Influenza NP (311-325) TFA is an Influenza A nucleoprotein peptide. Influenza NP (311-325) TFA is a class II restricted epitope. Influenza NP (311-325) Influenza NP (311-325) TFA fused to OVA protein can be used for immunological response studies.
  • HY-P5898
    Z-Val-Val-Nle-diazomethylketone
    		Inhibitor
    Z-Val-Val-Nle-diazomethylketone is a cathepsin S (CATS) inhibitor. Z-Val-Val-Nle-diazomethylketone significantly inhibits the IFNg-induced upregulation of the MHCII molecules HLA-DR and Ii-p33/35 with an increase of Ii-p10 protein level. Z-Val-Val-Nle-diazomethylketone can be used for dermatological diseases like psoriasis, atopic dermatitis and actinic keratosis research.
  • HY-123876
    AS2677131
    		Inhibitor
    AS2677131 is a potent and orally active PIKfyve inhibitor. AS2677131 inhibits f IL-12p40, IL-6 and IL-1β through a PIKfyve-c-Rel pathway. AS2677131 selectively inhibits DNA-binding activity of c-Rel to IL-12p40 and IL-1β promoter. AS2677131 inhibits MHC class II expression on B cells. AS2677131 can be used for the researches of inflammation and immunology, such as arthritis.
  • HY-177091
    AS2795440
    		Inhibitor
    AS2795440 is a PIKfyve inhibitor. AS2795440 selectively inhibits proinflammatory cytokine such as IL-12p40 and IL-6 production and B cell activation without affecting Ca2+ signaling. AS2795440 significantly reduces joint inflammation and bone loss in adjuvant-induced arthritis (AIA) mice model. AS2795440 can be used for inflammatory and autoimmune diseases like rheumatoid arthritis, psoriasis and inflammatory bowel disease research.
  • HY-P992408
    MEDI-5083
    		Activator
    MEDI-5083 is an Fc fusion protein that targets CD40 and is a CD40 agonist. MEDI-5083 stimulates CD40 signaling via NF-κB activation. MEDI-5083 upregulates MHCII, CD80, and CD86 expression, induces pro-inflammatory cytokine secretion, and enhances IFN-γ secretion by memory CD8+ T cells. MEDI-5083 can be used for the research of melanoma, colon carcinoma, and advanced solid tumors[1][2].
  • HY-W387035
    D-α-Methyl DOPA
    D-α-Methyl DOPA is an inhibitor of the binding of DQ8 peptide to MHC class II molecules. D-α-Methyl DOPA occupies a pocket along the DQ8 peptide binding groove. D-α-Methyl DOPA inhibits the binding of a DQ8 peptide to an MHC class II molecule for presentation to CD4+ T cells, thereby slowing the development or progression of type 1 diabete or celiac disease.
  • HY-105488
    MDL 201112
    MDL 201112 is a carbocyclic nucleoside. MDL 201112 can decrease TNF-α production and inhibit MHC class II Ia+ antigen expression. MDL 201112 can be used for the research of inflammation and immunology.